IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s What Happened

IPSEN (OTCMKTS:IPSEY)’s share price gapped down before the market opened on Monday . The stock had previously closed at $47.68, but opened at $44.9475. IPSEN shares last traded at $44.9475, with a volume of 1,023 shares trading hands.

Analysts Set New Price Targets

A number of brokerages have recently commented on IPSEY. HC Wainwright reissued a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Zacks Research raised shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, Jefferies Financial Group cut IPSEN to an “underperform” rating in a research note on Sunday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold”.

IPSEN Stock Performance

The business has a 50 day moving average price of $45.87 and a two-hundred day moving average price of $45.56.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).